BHBenjamin Heigle

Benjamin Heigle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benjamin Heigle has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical trial data-sharing policies among journals, funding agencies, foundations, and other professional organizations: a scoping review

    by Austin L. Johnson, J. Michael Anderson, Max Bouvette, Israel Pinero, Shelby Rauh, Bradley Johnson, Micah Kee, Benjamin Heigle, Andrea C. Tricco, Matthew J. Page, et al.


  • Open Access

    REPORTING OF PATIENT-REPORTED OUTCOMES IN RCTS FOCUSED ON TINNITUS: A META STUDY

    by Rigel Bacani, Kelsey Snider, Sam Jacobsen, Chase Ladd, Benjamin Heigle, Micah Kee, Cody Hillman, Ryan Ottwell, Micah Hartwell, Matt Vassar

    Background: The inclusion of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) supplements outcomes of treatment efficacy with the patient’s perspectives. The aim of this study was to evaluate reporting completeness of PROs in RCTs pertaining to tinnitus, using the Consolidated Standards of Reporting Trials (Consort-PRO) adaptation.Material and methods: We performed a search of Medline, Embase, and Cochrane Central Register of Controlled Trials (Central) for published RCTs related to tinnitus with at least one PRO measure from 2006 to 2020. Two investigators screened RCTs for inclusion. Using the Consort-PRO adaptation in an independent, masked fashion, investigators then evaluated all included RCTs. Similarly, all RCTs were evaluated using the Cochrane Collaboration Risk of Bias 2.0 tool. To assess relationships between trial characteristics and completeness of reporting, bivariate regression analyses were used.Results: From 878 publications, 37 RCTs met inclusion criteria. The mean Consort-PRO completeness of reporting across RCTs was 51.2% (SD = 20.8). Evaluation of our secondary outcome – assessment of study characteristics – demonstrated significantly higher completeness of reporting when (1) the Consort guideline was mentioned within the RCT (p = 0.01); (2) trials had ‘some concerns’ for bias (p = 0.001); and (3) trials had ‘low’ risk of bias (p = 0.001).Conclusions: Our study found that there was subpar Consort-PRO adherence within tinnitus RCTs. Due to the variance in symptom severity in tinnitus and the importance of PROs to clinical practice, we recommend journals include instructions to authors to use the Consort-PRO guideline before they publish RCTs.

  • Open Access

    Sickle Cell Disease and Quality of Life: An Evaluation of Reporting of Patient-Reported Outcomes in Randomized Controlled Trials

    by Abbey Renner, Mitchell Love, Elizabeth Garrett, Alexander Douglas, Micah Kee, Benjamin Heigle, Audrey Wise, Ryan Ottwell, Micah Hartwell, Matt Vassar

    Sickle cell disease significantly impacts one’s quality of life (QOL); thus, randomized controlled trials (RCTs) have integrated patient-reported outcomes (PROs) to assess patients’ health from their perspective. We aim to evaluate the completeness of reporting of PROs included in sickle cell disease RCTs. We searched MEDLINE, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) for published sickle cell disease RCTs with at least one PRO measure from 2006 to 2021. In a masked, duplicate fashion, two investigators evaluated RCTs using the Consolidated Standards of Reporting in Trials (CONSORT)-PRO adaptation and Cochrane Collaboration Risk of Bias (RoB) 2.0 tool. The primary objective was mean percent completeness of the CONSORT-PRO adaptation. Additional relationships between trial characteristics and completeness of reporting were evaluated. Mean completeness of reporting of RCTs was 41.49% (SD = 20.90). Randomized controlled trials with primary outcomes were more complete (57.50%, SD = 8.33) than RCTs with secondary PROs (33.48%, SD = 20.91). We did not find a significant difference in completion between trials with primary PROs and secondary PROs (t1 = 2.07; p = 0.06). Our secondary objectives included factors that may be associated with completeness of PRO reporting. Of the 12 included studies, five were considered to be overall ‘high’ RoB (41.67%). In each of the five domains, the majority of studies received ‘low’ RoB evaluations. Incomplete PRO reporting was common within sickle cell RCTs. Therefore, we recommend future RCTs including PROs should take measures to increase completeness of reporting.

  • Evaluating Reporting Completeness of Patient-Reported Outcomes in Esophageal Motility Disorders: A Cross-Sectional Analysis of Randomized Controlled Trials

    by Jordan Staggs, Cole Williams, Mitchell Love, Abbey Renner, Micah Kee, Cody Hillman, Samuel Shepard, Benjamin Heigle, Shelby Rauh, Ryan Ottwell, et al.

    Esophageal motility disorders (EMD) can have significant effects on quality of life. Patient-reported outcomes (PROs) provide valuable insight into the patient’s perspective on their treatment and are becoming increasingly used in randomized controlled trials (RCTs). Thus, our investigation aims to evaluate the completeness of reporting of PROs in RCTs pertaining to EMDs. We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials for published RCTs focused on EMDs. Included RCTs were published between 2006 and 2020, reported a primary outcome related to an EMDs, and listed at least one PRO measure as a primary or secondary outcome. Investigators screened and extracted data in a masked, duplicate fashion. Data extraction was carried out using both the CONSORT-PRO adaptation and Cochrane Collaboration Risk of Bias 2.0 tool. We assessed overall mean percent completion of the CONSORT-PRO adaptation and a bivariate regression analysis was used to assess relationships between trial characteristics and completeness of reporting. The overall mean percent completion of the CONSORT-PRO checklist adaptation was 43.86% (SD = 17.03). RCTs with a primary PRO had a mean completeness of 47.73% (SD = 17.32) and RCTs with a secondary PRO was 35.36% (SD = 13.52). RCTs with a conflict of interest statement were 18.15% (SE = 6.5) more complete (t = 2.79, P = .009) than trials lacking a statement. No additional significant associations between trial characteristics and completeness of reporting were found. PRO reporting completeness in RCTs focused on EMDs was inadequate. We urge EMD researchers to prioritize complete PRO reporting to foster patient-centered research for future RCTs on EMDs.

  • Open Access

    Correction: The Use of Person-Centered Language in Medical Research Journals Focusing on Psoriasis: Cross-sectional Analysis

    by Ryan Ottwell, Benjamin Heigle, Arjun K Reddy, Nicholas Sajjadi, Alexis Wirtz, Courtney Cook, Hannah Howard, Micah Hartwell, Matt Vassar

    [This corrects the article DOI: 10.2196/28415.].

  • Open Access

    Correction: The Use of Person-Centered Language in Medical Research Journals Focusing on Psoriasis: Cross-sectional Analysis (Preprint)

    by Ryan Ottwell, Benjamin Heigle, Arjun K Reddy, Nicholas Sajjadi, Alexis Wirtz, Courtney Cook, Hannah Howard, Micah Hartwell, Matt Vassar

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).


  • Open Access

    The Use of Person-Centered Language in Medical Research Journals Focusing on Psoriasis: Cross-sectional Analysis

    by Ryan Ottwell, Benjamin Heigle, Arjun K Reddy, Nicholas Sajjadi, Alexis Wirtz, Courtney Cook, Hannah Howard, Micah Hartwell, Matt Vassar

    Background: Person-centered language places a person’s identity before any disability or medical condition they may have. Using person-centered language reduces stigma and improves the patient-physician relationship, potentially optimizing health outcomes. Patients with psoriasis often feel stigmatized due to their chronic skin condition. Objective: We seek to evaluate the use of person-centered language in psoriasis literature and to explore whether certain article characteristics were associated with non–person-centered language. Methods: We performed a systematic search on PubMed for recently published articles in journals that regularly publish psoriasis studies. After article reduction procedures, randomization, and screening, we reached our target sample of 400 articles. The following non–person-centered language terms were extracted from each article: “Psoriasis Patient,” “Psoriasis subject,” “Affected with,” “Sufferer,” “Suffering from,” “Burdened with,” “Afflicted with,” and “Problems with.” Screening and data extraction occurred in a masked duplicate fashion. Results: Of the 400 included articles, 272 (68%) were not adherent to person-centered language guidelines according to the American Medical Association Manual of Style. The most frequent non–person-centered language term was “Psoriasis Patient,” found in 174 (43.5%) articles. The stigmatizing language was associated with the type of article and funding status, with original investigations and funded studies having higher rates of stigmatizing language. Conclusions: Articles about psoriasis commonly use non–person-centered language terms. It is important to shift away from using stigmatizing language about patients with psoriasis to avoid potential untoward influences. We recommend using “patients with psoriasis” or “patient living with psoriasis” to emphasize the importance of person-centered care.


  • Spin the Abstracts of Systematic Reviews and Meta-Analyses Regarding the Treatment of Ménière’s Disease:

    by Benjamin Heigle, Micah Kee, Ryan Ottwell, Wade Arthur, Lacy Brame, Drew N. Wright, Micah Hartwell, Jam Khojasteh, Matt Vassar

    To identify, quantify, and characterize the presence of spin—specific strategies leading to misrepresentation of study results—in the abstracts of systematic reviews and meta-analyses of Ménière’s disease treatment. Using a cross-sectional design, we searched MEDLINE and Embase on May 28, 2020, for systematic reviews and meta-analyses focused on Ménière’s disease treatment. Returned searches were screened, and data were extracted in a masked, duplicate fashion. Our sample included 36 systematic reviews and meta-analyses. Of the 36 included studies, 22 (61.1%) abstracts contained spin while 14 (38.9%) did not. The most common spin types were selective reporting of benefit (10/36, 27.8%) or harm (8/36, 22.2%). Other types of spin occurred when findings were extrapolated to the global improvement of the disease (5/36, 13.9%), beneficial effects were reported with high risk of bias in primary studies (3/36, 8.3%), and when beneficial effects were extrapolated to an entire class of interventions (1/36, 2.8%). No instances of other spin types occurred. Abstracts containing spin were substantively associated with studies of critically low methodological quality compared with studies with low and moderate quality. No studies had a methodological rating of high quality. No associations were observed between spin and intervention types, journal recommendation of adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses, or funding. We found a negative correlation (r = −.31) between abstract word limit and presence of spin. Our study highlights that spin in the abstracts of systematic reviews of Ménière’s disease is common, and it further enhances the discussion surrounding spin in abstracts of scientific research. Spin in an abstract does not discredit a study’s findings; however, its occurrence should be eliminated.


  • Open Access

    The influence of industry sponsorship and conflict of interest on results and conclusions of systematic reviews regarding treatment of knee osteoarthritis

    by Benjamin Heigle, Samuel Shepard, J. Michael Anderson, Michael Weaver, Micah Hartwell, Matt Vassar